Half-Life (Normalesrd) Hours
2.7 min/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
0.357
Dose For Normal Renal Function
2 ng/kg/min infusion
Second Dose
Second Dose: 2-12 ng/kg/min
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 0.5 to 12 ng/kg/min,titrate, [B]
References
Hildebrand M. Inter-species extrapolation of pharmacokinetic data of three prostacyclin-mimetics. Prostaglandins. 1994; 48: 297-312. [PMID: 7531864] / Smith MC, Danviriyasup K, Crow JW, Cato AE, Park GD, Hassid A, et al. Prostacyclin substitution for heparin in long-term hemodialysis. Am J Med. 1982; 73: 669-78. [PMID: 6753575] / Swartz RD, Flamenbaum W, Dubrow A, Hall JC, Crow JW, Cato A. Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications. J Clin Pharmacol. 1988; 28: 818-25. [PMID: 3068260]
Toxicity Notes
No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol. Data are for animal studies.